Who are GSK 573719 125's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): UMEC/VI, Budesonide/formoterol and tiotropium, UMEC/VI DPI, umeclidinium bromide (UMEC), UMEC DPI, tiotropium bromide inhalation powder HandiHaler.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gsk-573719-125.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

GSK 573719 125 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GSK 573719 125 (GSK 573719 125) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting muscarinic antagonist (LAMA). Area: Respiratory / Pulmonology.

phase 3 Long-acting muscarinic antagonist (LAMA) Muscarinic M3 receptor Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

GSK 573719 125 (GSK 573719 125) — GlaxoSmithKline. GSK573719 is a long-acting muscarinic antagonist (LAMA) that blocks M3 receptors in airway smooth muscle to promote bronchodilation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
GSK 573719 125 TARGET	GSK 573719 125	GlaxoSmithKline	phase 3	Long-acting muscarinic antagonist (LAMA)	Muscarinic M3 receptor
UMEC/VI	UMEC/VI	GlaxoSmithKline	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor; beta-2 adrenergic receptor
Budesonide/formoterol and tiotropium	Budesonide/formoterol and tiotropium	Brian J Lipworth	marketed	Combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist	Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
UMEC/VI DPI	UMEC/VI DPI	GlaxoSmithKline	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor (umeclidinium); Beta-2 adrenergic receptor (vilanterol)
umeclidinium bromide (UMEC)	umeclidinium bromide (UMEC)	GlaxoSmithKline	marketed	Long-acting muscarinic antagonist (LAMA)	Muscarinic M3 receptor
UMEC DPI	UMEC DPI	GlaxoSmithKline	marketed	Long-acting muscarinic antagonist (LAMA)	Muscarinic M3 receptor
tiotropium bromide inhalation powder HandiHaler	tiotropium bromide inhalation powder HandiHaler	GlaxoSmithKline	marketed	Long-acting muscarinic antagonist (LAMA)	Muscarinic M3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting muscarinic antagonist (LAMA) class)

GlaxoSmithKline · 9 drugs in this class
AstraZeneca · 3 drugs in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Chiesi Farmaceutici S.p.A. · 1 drug in this class
IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
Lupin, Inc. · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GSK 573719 125 — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk-573719-125. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab